Overview
- The subsequent-offer period closed on December 18 with 195,341,219 CureVac shares tendered, equal to 86.75% of outstanding stock.
- BioNTech expects to complete the mandatory acquisition of remaining shares in January 2026 under the announced reorganization, after which CureVac securities will be delisted.
- BioNTech said Ugur Sahin, Sierk Poetting and Ramón Zapata-Gomez will form CureVac’s board following the voluntary resignation of prior members.
- CureVac will continue day-to-day operations under existing processes as BioNTech finalizes strategic, operational and scientific assessments to define the future structure.
- The transaction also ends the companies’ COVID-19 vaccine patent dispute, which they agreed to settle in August in connection with the takeover.